著名精神病学家推出成瘾治疗的突破性疗法-动脉网

Prominent Psychiatrist Introduces Breakthrough Treatment for Addiction

CISION 等信源发布 2025-04-18 02:35



可切换为仅中文







NEW YORK

纽约

，

April 17, 2025

2025年4月17日

/PRNewswire/ -- Dr. DiFrancesco (

/PRNewswire/ -- DiFrancesco博士（

www.xsrxdoctor.com

) is deeply enthusiastic about new developments in the treatment of addiction and has launched a new website for individuals who would like to learn more and are seeking treatment.

）对成瘾治疗的新进展充满热情，并为那些希望了解更多并正在寻求治疗的个人推出了一个新网站。

Experience the full interactive Multichannel News Release here:

在此体验完整的交互式多渠道新闻稿：

https://www.multivu.com/xsrxdoctor/9329051-en-dr-difrancesco-breakthrough-treatment-for-addiction

继续阅读

Dr. Eileen DiFrancesco Introduces Breakthrough Treatment For Addiction

迪弗朗切斯科博士介绍了一种突破性的成瘾治疗方法。

Dr. Eileen DiFrancesco Introduces Breakthrough Treatment For Addiction

迪弗朗切斯科博士介绍了针对成瘾的突破性治疗方法

Dr.

博士

Eileen DiFrancesco

艾琳·迪弗朗切斯科

a physician in

医生在

New York City

纽约市

has specialized in Psychiatry and Psychopharmacology for over two decades treating a wide variety of neuropsychiatric disorders, focusing on addiction.

在精神病学和精神药理学领域有二十多年的经验，治疗各种神经精神障碍，专注于成瘾。

She has had the opportunity to train in Ivy League schools and work in the ivory towers of Medicine, but unfortunately, she says there has never been an effective medication for the treatment of addiction - until now.

她曾有机会在常春藤盟校接受培训，并在医学的象牙塔中工作，但她说，遗憾的是，迄今为止还没有一种有效的药物可以治疗毒瘾——直到现在。

Patients who are taking the popular drug Ozempic, also known as semaglutide which was developed for the treatment of diabetes and weight loss are experiencing remarkable results. Surprisingly, they are not only reporting a decrease in the over consumption of food, but also little or no interest in alcohol..

服用流行药物Ozempic（又称为司美格鲁肽，该药物用于治疗糖尿病和减肥）的患者正在获得显著的效果。令人惊讶的是，他们不仅报告过度饮食行为减少，而且对酒精的兴趣也变得很少甚至毫无兴趣。

DiFrancesco says this is not a coincidence or a side effect. As published in JAMA, Nature and Science Direct -these medications target neural circuits involved in reward and satiety and therefore greatly curb craving for addictive substances.

迪弗朗切斯科说，这不是巧合，也不是副作用。正如《美国医学会杂志》、《自然》和《科学直接》所发表的那样——这些药物针对与奖励和饱腹感相关的神经回路，因此大大抑制了对成瘾物质的渴望。

Semaglutide and a similar medication tirzepatidetide are medication's that mimic a natural hormone called glucagon -like peptide – 1 or GLP -1. These hormones are activated when the GLP one receptor agonist attached to their receptors.

Semaglutide 和一种类似药物 tirzepatide 是模拟一种名为胰高血糖素样肽 -1 或 GLP-1 的天然激素的药物。当 GLP-1 受体激动剂附着在它们的受体上时，这些激素被激活。

What is truly exciting is that GLP one receptors are all over the brain reward pathway. This pathway exists to provide a sense of pleasure or reward when we do something that is essential for our survival or survival of the species such as eating healthy foods having sex and nurturing relationship relationships..

真正令人兴奋的是，GLP-1受体遍布大脑的奖励通路。该通路的存在是为了在我们做一些对我们的生存或物种生存至关重要的事情时，提供一种愉悦感或奖励感，例如吃健康的食物、发生性行为以及培养人际关系。

The reward or sense of pleasure is intended to make us repeat these behaviors so that our species will survive because we eat well, procreate and take care of others. However, substances and things that are highly pleasurable can take over these reward circuits. This causes the natural rewards to become less pleasurable and even ignored..

奖励或愉悦感旨在让我们重复这些行为，这样我们的物种才能因为饮食健康、繁衍后代和照顾他人而生存下来。然而，高度愉悦的物质和事物会占据这些奖励回路，这会导致自然奖励变得不那么愉悦，甚至被忽略。

This is what addictive substances do, they hijack the reward pathway in such a way that they become the focus of an individual's life.

这就是成瘾物质的作用，它们劫持了奖励通路，从而成为一个人生活的焦点。

According to JAMA, a nationwide register based study with GLP one receptor agonist Semaglutide were associated with a markedly, reduced risk of alcohol use disorders and substance use disorder related hospitalizations. In the journal nature, the administration of GLP one has convincingly shown to reduce alcohol intake and pre-clinical models.

根据《美国医学会杂志》报道，一项基于全国登记的 GLP-1 受体激动剂司美格鲁肽研究显示，其与显著降低的酒精使用障碍和物质使用障碍相关住院风险有关。在《自然》期刊中，GLP-1 的使用已被令人信服地证明可以减少酒精摄入量并在临床前模型中生效。

Observational studies clearly show that GLP one receptor Agnes are associated with non-volitional reduction and the use of alcohol, nicotine, cocaine and opioids..

观察性研究清楚地表明，GLP-1受体激动剂与非自主减少酒精、尼古丁、可卡因和阿片类药物的使用有关。

When GLP one receptor agonist activate the GLP one receptors in the reward pathway, the sense of reward from the addictive substances, including alcohol, nicotine cocaine, and even opioid becomes less rewarding. This serendipitous finding is truly amazing and wonderful.

当GLP-1受体激动剂激活奖赏通路中的GLP-1受体时，包括酒精、尼古丁、可卡因甚至阿片类物质在内的成瘾物质所带来的奖赏感会变得不那么有吸引力。这一意外发现真是令人惊叹和奇妙。

When combined with already existing treatment for addiction, DiFrancesco Psychiatry feels there is finally help and hope for treating this destructive and debilitating disease.

当与已有的成瘾治疗相结合时，DiFrancesco 精神病学认为终于有了帮助和希望来治疗这种破坏性和使人衰弱的疾病。

If you or someone you love is suffering and would like to learn more, please contact us at:

如果您或您所爱的人正在遭受痛苦并想了解更多信息，请通过以下方式联系我们：

Help@xsrxdoctor.com

帮助@xsrxdoctor.com

。

About Dr.

关于博士

Eileen DiFrancesco

艾琳·迪弗朗切斯科

Dr.

博士

Eileen DiFrancesco

艾琳·迪弗朗切斯科

graduated with honors from the

以优异成绩毕业于

University of Pennsylvania

宾夕法尼亚大学

where she received her Bachelor's Degree. After earning a medical degree from

她在那裡獲得了學士學位。之後，又從

Temple University

天普大学

School of Medicine, she received additional training in both Psychiatry and Neurology.

医学院，她接受了精神病学和神经学的额外培训。

Upon completing residency training at Mount Sinai Medical Center in

在西奈山医疗中心完成住院医师培训后

New York City

纽约市

she was appointed Medical Director of the Learning Laboratory, a private facility in

她被任命为学习实验室的医学主任，这是一个私人设施

Connecticut

康涅狄格州

. There she specialized in diagnosing and treating Attention Deficit Disorder, Addiction, Depression and Bipolar Disorder, using Quantitative EEG also known as Brain Mapping.

在那里，她专攻于利用定量脑电图（也称为脑图）诊断和治疗注意力缺陷障碍、成瘾、抑郁症和双相情感障碍。

Her diagnostic skills were also utilized at the Mount Sinai School of Medicine where she assessed psychotic adolescents for Schizophrenia treatment and eligibility for research protocols.

她的诊断技能也在西奈山医学院得到应用，在那里她评估了患有精神病的青少年，以确定他们是否适合接受精神分裂症治疗及参与研究方案的资格。

SOURCE xsrxdoctor

来源 xsrxdoctor

WANT YOUR COMPANY'S NEWS

想要你公司的新闻

FEATURED ON PRNEWSWIRE.COM?

刊登在PRNEWSWIRE.COM上？

440k+

44万+

Newsrooms &

新闻编辑室 &

Influencers